Schedule 13G ownership disclosure
INOZYME PHARMA INC
Common Stock, par value $0.0001 per share · CUSIP: 45790W108
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Samlyn Capital, LLC
Shares: 0.00 · Class: 0%
- Samlyn, LP
Shares: 0.00 · Class: 0%
- Robert Pohly
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-25-001473
- Form type
- SCHEDULE 13G/A
- Filer
- Inozyme Pharma, Inc.
- CIK
- CIK 1693011
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership